Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China · Delayed Price · Currency is CNY

32.37

-0.13 (-0.40%)

Oct 23, 2026, 10:55 AM CST

Market Cap	29.01B -23.0%
Revenue (ttm)	4.48B +257.0%
Net Income	3.09B +302.4%
EPS	3.47 +304.3%
Shares Out	896.23M
PE Ratio	9.33
Forward PE	45.77
Dividend	0.33 (1.03%)
Ex-Dividend Date	Jun 18, 2026

Volume	3,306,435
Open	32.00
Previous Close	32.50
Day's Range	31.47 - 32.64
52-Week Range	31.58 - 66.62
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for t... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 1,023

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688336

Full Company Profile

Financial Performance

In 2025, SHA:688336's revenue was 4.20 billion, an increase of 251.81% compared to the previous year's 1.19 billion. Earnings were 2.90 billion, an increase of 311.49%.

Financial Statements